The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 21, 2023

Filed:

Apr. 20, 2017
Applicants:

Ecole Normale Superieure DE Lyon, Lyons, FR;

Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;

Université Claude Bernard Lyon 1, Villeurbanne, FR;

Institut National DE LA Sante ET DE LA Recherche Medicale (Inserm), Paris, FR;

Inventors:

Caroline Costa Fejoz, Lyons, FR;

Els Verhoeyen, Nice, FR;

François-Loïc Cosset, Lyons, FR;

Ruben Bender, Frankfurt, DE;

Christian Buchholz, Frankfurt, DE;

Qi Zhou, Hitchin, GB;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/86 (2006.01); A61P 35/00 (2006.01); C07K 14/005 (2006.01); C07K 14/54 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61P 35/00 (2018.01); C07K 14/005 (2013.01); C07K 14/5418 (2013.01); C07K 16/2812 (2013.01); C07K 16/2815 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/74 (2013.01); C12N 2740/16043 (2013.01); C12N 2740/16045 (2013.01); C12N 2760/18222 (2013.01); C12N 2760/18422 (2013.01);
Abstract

The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.


Find Patent Forward Citations

Loading…